• The School provides more than $200,000 in seed money to enhance drug discovery and entrepreneurial efforts.

• Lonnie and Sharon Moulder donate an additional $500,000 to TUSP to establish the Moulder Center for Drug Discovery Research.

• Dr. Abou-Gharbia joins TUSP as a tenured professor and becomes founding director of the Moulder Center.

• The Moulder Center is dedicated on May 13, 2009.

• Temple University School of Pharmacy and The Moulder Center receives an NIH RC1 Challenge grant entitled “β-Lactam Chemical Probes for GLT-1 Transporter Related Pathologies” (5RC1DA028153-01, 2009 $478,707, 2010 $477,042).

• Temple University’s Drug Discovery Initiative proposal is awarded $8.3 MM in funding to support expansion of the Moulder Center.
• The Moulder Center adds 5 new faculty members in the department of Pharmaceutical Sciences (4 tenure track, 1 research track), an in vitro screening manager, 4 research scientists, and 1 postdoctoral fellow.
• Shifa Biomedical Corporation and The Moulder Center receive an NIH SBIR phase 2 grant entitled “Structure-Based Search for Novel Antihypercholestrolemic Agents” (2R44HL092712, 2010 $ $681,349, 2011 $ 655,327).

• The Moulder Center enters a 2 year, $2.1M collaboration with Cortendo AB to develop novel Cyp17 inhibitors for the treatment of metabolic syndrome.
• Partnership with GVK Bio is created to support development of novel treatments for Metabolic Syndrome.
• Receive a Pennsylvania Department of Health grant entitled “Temple University PET/SPECT initiative” for $500,000.
• The Moulder Center establishes a collaboration with the University of Rochester School of Medicine and Dentistry to translate novel medical research into new drugs for treating diseases.

• Collaboration with the Wistar Institute is established, focused on the discovery of small molecule anticancer agents.
• South Dakota State University and The Moulder Center receive a grant from the State of South Dakota entitled “Novel Inhibitors of FMS Kinase for the Treatment of Metastatic Breast Cancer” for $28,500.
• Shifa Biomedical Corporation and The Moulder Center receive an NIH SBIR Phase 2 grant entitled “Novel Modulators of HDL Metabolisms” (2R44HL097438-02A1) for $785,643.

• Partnership with Dotmatics, Inc. is created to enhance drug discovery programs.
• The Moulder Center receives a University Science Center QED grant entitled “GLT-1 Expression Modulator Useful for the Treatment of Amyotrophic Lateral Sclerosis for $200,000.

The Moulder Center, John Hopkins University, the University of Florida, and the University of Rochester receive a NIDA grant entitled “GLT-1 Enhancers for Treating Cocaine Addiction” (R01DA037270, $1.8M). 2014 $ 348,739, 2015 $372,311, 2016 $377,257, 2017 $375,351, 2018 $504,440).

· Temple University School of Medicine and The Moulder Center receive an NCI grant entitled “Targeting DNA repair to eradicate TKI-refractory/resistant CML” (1R01CA186238-01, 2014 $537,724, 2015 $531,250, 2016 $531,250, 2017 $504,699, 2018 $490,024 Renewed in 2020 $380,072, 2021 $380,072, 2022 $388,003, 2023 $389,5570).

· The University of Texas Health Science Center, The Moulder Center, Arizona State University, and the University of Pennsylvania receive an NIH grant entitled “D3 Receptor Compounds for the Treatment of Psychostimulant Abuse” (R01DA023957, 2015 $677,268, 2016 $633,194, 2017 $636,340).

· The Moulder Center receives an NIH grant to support the purchase of an FDSS uCell Kinetic Plate Reader (1S10OD018195-01, $266,700).

· Montclair State University and The Moulder Center receive a DOD grant entitled “Discovery and Optimization of Botulinum Neurotoxin Protease Inhibitors.” (W81XVVH-14-C-0090, $734,760).

· Temple University School of Medicine and The Moulder Center receive a DOD grant entitled “Identifying Compounds for Targeted Breast Cancer Treatment and Prevention” (W81XWH-14-1-0344, $531,359).

· The Moulder Center establishes a collaboration with MorphoSys AG, a global leader in antibody phage display technology, to develop novel antibody therapeutics using the Ylanthia® library.

• Temple School of Pharmacy receives an endowment of $4.275M for the Moulder Center for Drug Discovery Research from Lonnie and Sharon Moulder.
• Cognition Therapeutics and The Moulder Center receive an NIH SBIR Phase 1 grant entitled “Novel Sigma-2 Receptor Modulators for the Treatment of Cognitive Dysfunction” (1R41AG052249-01, $298,527, 2015-2016).

• The Moulder Center and the University of Pennsylvania receive a grant from the Million Dollar Bike Ride entitled Patient Derived Phenotypic High Throughput Screen to Discover Treatments for Tay-Sachs Disease (MDBR-16-115-TSA, $42,997).
• The Moulder Center and Temple University School of Medicine receive a grant from the Mary Kay Foundation entitled “Targeting DNA Polymerase q for Precision Medicine in BRCA Deficient Breast Cancer” (Grant No. 033.16, $100,000).
• The Moulder Center and Temple University School of Medicine receive an NCI grant entitled “Development of DNA Polymerase q Inhibitors for Precision Medicine in BRCA Deficient Cancers” (5R21CA209281-01, 2016 $201,144, 2017 $169,650).
• Alfred I. DuPont Hospital for Children and the Moulder Center receive an NIH grant entitled “Assay Development for NSD1 Methyltransferase Inhibitor Discovery” (1R01CA191077, 2015 $295,711, 2016 $312,244, 2017 $312,244).

• Moulder Center receives a grant from the PA Department of Human Services (Grant #420843, $50,000) to study GLT-1 enhancer in models of traumatic brain Injury.
• Temple University launches Praeventix LLC to facilitate commercialization of IBD therapies discovered at the Moulder Center and Temple School of Pharmacy.
• Praeventix LLC and The Moulder Center receive an NIH SBIR Phase 1 grant entitled “Novel 5-HT7 Antagonists for the Treatment of Inflammatory Bowel Disease” (1R43DK115254, $231,801).
• The Moulder Center and Temple School of Pharmacy receive a grant from the Crohn’s and Colitis Foundation entitled “Novel Therapies for the Treatment of Ulcerative Colitis: 5-HT7 Antagonists” ($321,878, ref#510490).
• The Moulder Center and Temple University School of Medicine receive a grant from Shriner’s Hospital for Children entitled “High-Content Screening to Identify a Novel Class of Neuroprotectants” (Project No. 87400, $120,000).
• Temple University School of Medicine and The Moulder Center receive an NCI grant entitled “Normal ABL1 Kinase as Tumor Suppressor and Therapeutic Target in Leukemia” (1R01CA216813-01, 2017, $485,639, 2018, $485,369, 2019 $470,806, 2020, $486,669, 2021 $486,669).
• Rutgers University and The Moulder Center receive an NIH grant entitled “Development of inhibitors of P. falciparum cGMP dependent protein kinase (PfPKG) for malaria chemoprevention” (1R01AI133633-01, 2017, $721,174, 2018 $701,820, 2019, $694,721).
• The University of North Dakota and the Moulder Center receive a DOD grant entitled “Novel Targeted Therapeutics for Castration-resistant Prostate Cancer” (W81XWH1710169, $899,523).

• The Fels Cancer Institute and the Moulder Center receive a University Science Center QED grant entitled “A New Cyclin Dependent Kinase inhibitor selective for CDK9 and CDK4” ($200,000).
• Praeventix LLC and The Moulder Center receive an NIDDK SBIR phase 2 grant entitled “Novel 5-HT7 Antagonists for the Treatment of Inflammatory Bowel Disease” (2R44DK115254, 2018 $1,228,145, 2019 $1,228,145).
• Temple University School of Medicine and The Moulder Center receive an NIH grant entitled “Discovery and Mechanism of Bk Channel Gating Modulators” (1R01GM126581-01A1, 2018 $333,229, 2019 $317,000, 2020 $317,000, 2021 $317,000, 2021S $84,207)).
• MD Anderson Cancer Center at the University of Texas, The Moulder Center, and the Fels Cancer Institute receive an NIH grant to support the Specialized Program of Research Excellence (SPORE) in Leukemia at the MD Anderson Cancer Center (2P50CA100632-16, 2018, $1,392,864).
• University of Pennsylvania and the Moulder Center receive an NIH R01 grant entitled “Development of Braf Dimer Inhibitors To Treat Drug Resistant Melanoma” (1R01CA226888-A101, 2019, $667,564, 2020 $731,727, 2021 $643,599, 2022 $631,536, 2023 $642,782).

• Praeventix LLC and the Moulder Center receive an NIDA SBIR Phase 1 grant entitled “In vivo Characterization of PRA078C in the Rat Cocaine Reinstatement Model” (1R43DA50400, $350,000K).
• The Moulder Center receives a grant from the Michael J Fox Foundation entitled “Investigating the Effect of Small Molecules to Rescue Lysosomal and GBA-1 Deficiencies in GBA-PD” (Grant #16608, $143,611).
• Temple University School of Medicine and the Moulder Center receive an NIH grant entitled “Palmitoylation-Dependent Control of Glaucomatous Neurodegeneration” (1R21EY029386-01A1, $253,798).
• The Moulder Center receives an NIH grant entitled “Folding Assisted Therapeutics for Achromatopsia” (1R21EY030257-01, $198,125).

• · Temple University School of Medicine and the Moulder Center receive an NCI grant entitled “PolQ as a Novel Therapeutic Target in AML” (1R01CA244179-01, 2020 $298,959, 2021 $556,097, 2022 $535,835, 2023 $523,880, 2024 $473,617).
• Temple University launches Tamuro Bio to develop novel type 2 diabetes therapies discovered at the Moulder Center and Temple School of Pharmacy.
• Temple University and the Coriell Institute for Medical Research launch EpiGenOnco Therapeutics to develop novel epigenetic cancer therapies developed at the Moulder Center and Temple School of Pharmacy.
• Temple University School of Medicine and The Moulder Center receive a grant from Shriner’s Hospital for Children entitled “Exploiting Palmitoylation-dependent DLK Signaling to Identify Novel Neuroprotectants” (Program # 85190-PHI-20, $41,857).
• Temple University School of Medicine and the Moulder Center receive a DOD grant entitled “Targeting Pol-Theta as a Novel Breast Cancer Target” (W81XWH2010031, $650,158).
• Recombination Therapeutics and The Moulder Center receive an NCI phase 1 SBIR entitled “Next-generation precision medicine for targeting recombination-deficient cancers” (1R41CA239983-01A1, $298,959).
• Recombination Therapeutics and The Moulder Center receive an NCI phase 1 SBIR entitled “Nucleotide inhibitors as precision medicine in breast cancer” (1R41CA257002-01, $399,757).
• Montclair State University and the Moulder Center receive an NIA R01 grant entitled “Pharmacologic Inhibition of PDE11A for Age-related Memory Disorders” (1R01AG067836, $686,057).
• Daniel J. Canney appointed interim director of the Moulder Center.

• Recombination Therapeutics and The Moulder Center receive an NCI phase 1 SBIR entitled “Structure Based Design of Pol-theta inhibitors” (1R41CA265430-01, $385,900).
• Fox Chase Cancer Center and the Moulder Center receive a NIGMS R01 entitled “Designing Kinase Inhibitors Via Deep Learning: (1R01GM145513, $250,000).
• Thomas Jefferson University and the Moulder Center receive a Phase 1 Ralph and Marion Falk Medical Research Trust grant entitled “PROTACs for Targeting BRCA-deficient Cancers” (08-02000-U31701, $100,000).

• Praeventix LLC and the Moulder Center receive a NIDA SBIR Phase 1 entitled “In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder” (1R44DA055443-01A1, $320,000). · Praeventix LLC and the Moulder Center receive an NIAMS SBIR phase 1 entitled “Novel 5-HT7 Antagonists for the Treatment of Pruritus” (1R43AR081768-01, $275,544).
• Temple University College of Science and Technology and the Moulder Center receive a PA CURE grant entitled “Developing coronavirus main cysteine protease (M3CLpro) inhibitors” (2022 $335,025, 2023 $335,025).
• Vironika LLC and and the Moulder Center receive a NIAID SBIR phase 1 entitled “Discovery of inhibitors of EBV lytic cycle inducing protein ZTA for therapeutic development” (1R43AI167400-01, $269,073).
• The University of Toledo and the Moulder Center receive a grant entitled “Novel GLT-1 activators for the treatment of alcohol dependence: preclinical studies” (2022 $437,019, 2023 $430,579).
• John Karanicolas appointed Moulder Center director.

• Praeventix LLC and the Moulder Center receive a NIDA SBIR Phase 2 entitled “In Vivo Characterization of 5-HT7 Modulators in Rat Models of Cocaine Use Disorder” (4R44DA055443-02, $1,250,000).
• Thomas Jefferson University and the Moulder Center receive a Phase 2 Ralph and Marion Falk Medical Research Trust grant entitled “PROTACs for Targeting BRCA-deficient Cancers” (08-02000-U31701, $1,000,000).